HUP0301691A3 - Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use - Google Patents

Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use

Info

Publication number
HUP0301691A3
HUP0301691A3 HU0301691A HUP0301691A HUP0301691A3 HU P0301691 A3 HUP0301691 A3 HU P0301691A3 HU 0301691 A HU0301691 A HU 0301691A HU P0301691 A HUP0301691 A HU P0301691A HU P0301691 A3 HUP0301691 A3 HU P0301691A3
Authority
HU
Hungary
Prior art keywords
tipe
isoforms
cloning
expression
methods
Prior art date
Application number
HU0301691A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HUP0301691A2 publication Critical patent/HUP0301691A2/hu
Publication of HUP0301691A3 publication Critical patent/HUP0301691A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
HU0301691A 2000-04-03 2001-03-26 Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use HUP0301691A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19431800P 2000-04-03 2000-04-03
PCT/US2001/009664 WO2001074837A1 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
US09/817,676 US6800470B2 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Publications (2)

Publication Number Publication Date
HUP0301691A2 HUP0301691A2 (hu) 2003-08-28
HUP0301691A3 true HUP0301691A3 (en) 2005-04-28

Family

ID=26889896

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301691A HUP0301691A3 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use

Country Status (9)

Country Link
US (4) US6800470B2 (https=)
JP (1) JP4584525B2 (https=)
KR (1) KR20020093017A (https=)
AU (1) AU5100201A (https=)
CA (1) CA2404965A1 (https=)
DK (1) DK1268509T3 (https=)
HU (1) HUP0301691A3 (https=)
MX (1) MXPA02009781A (https=)
WO (1) WO2001074837A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009781A (es) * 2000-04-03 2004-09-06 Sankyo Co Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
AU2003292636A1 (en) * 2002-12-27 2004-07-29 The New Industry Research Organization Cell growth inhibitor using sphingosine kinase 2, method of constructing fused protein having its nuclear localization signal, method of screening drug candidate, and screening kit
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
CA3061201A1 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
CA2329124A1 (en) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
AU3828301A (en) * 2000-02-14 2001-08-27 Curagen Corp Novel sphingosine kinases
MXPA02009781A (es) * 2000-04-03 2004-09-06 Sankyo Co Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.

Also Published As

Publication number Publication date
KR20020093017A (ko) 2002-12-12
US6800470B2 (en) 2004-10-05
US20020042101A1 (en) 2002-04-11
CA2404965A1 (en) 2001-10-11
US7803595B2 (en) 2010-09-28
US20120107833A1 (en) 2012-05-03
DK1268509T3 (da) 2010-03-08
JP4584525B2 (ja) 2010-11-24
US8263349B2 (en) 2012-09-11
US7419814B2 (en) 2008-09-02
AU5100201A (en) 2001-10-15
HUP0301691A2 (hu) 2003-08-28
JP2004500117A (ja) 2004-01-08
WO2001074837A1 (en) 2001-10-11
MXPA02009781A (es) 2004-09-06
US20090169555A1 (en) 2009-07-02
US20040203104A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
AU5752601A (en) Splice-region antisense composition and method
IL162328A0 (en) Adjustable chair and method of use
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
AU1194802A (en) DNA expression vectors and methods of use
AU7334901A (en) Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
PL358406A1 (en) Enzyme-catalyzed polyamides and compositions and processes of preparing and using the same
SI0736525T1 (en) Benzonitriles as 5-HT agonists and antagonists
IL151518A0 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
HUP0301691A3 (en) Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use
DK1138677T3 (da) Fremgangsmåde til fremstilling af 11-amino-3-chlor-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepin og anvendelse til syntese af tianeptin
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
NZ332757A (en) Substituted tetrahydroisoquinoline benzamide derivatives and their use as anticonvulsants and psycho-active agents
ZA988921B (en) 3,4-diarylthiazolin-2-one or -2-thione derivatives their methods of preparation and their uses in therapeutics
ZA200106928B (en) Protection of keratinous fibers using ceramides and/or glycoceramides.
HUP0501056A2 (en) Use of cationic surface active agents and fiber softening compositions containing the same
PL360289A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
PL351301A1 (en) Novel inhibitors of metaloprotease, methods of obtaining them and pharmacological composition containing such inhibitors
EP1352637A4 (en) HAIRCARDANTS AND COMPOSITIONS COMPRISING THEM
AU3281401A (en) Antisense modulation of glycogen synthase kinase 3 alpha expression
HUP0200162A3 (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
HU0000039D0 (en) Use of cationic monobenzene nitroanalines in the dyeing of keratinous fibres, dyeing composition and dyeing processes